27 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Great Therapeutic Potential of Peptidylarginine Deiminase 4 (PAD4) Inhibitors: Treatment of Rheumatoid Arthritis, Epigenetic Tools, Regulation of Pluripotency in Stem Cells, and More.
Therachem Research Medilab (India)
Design, synthesis, and biological evaluation of tetrazole analogs of Cl-amidine as protein arginine deiminase inhibitors.
University of Massachusetts Medical School
Insights into the mechanism of streptonigrin-induced protein arginine deiminase inactivation.
The Scripps Research Institute-Florida
Interrogation of the Active Sites of Protein Arginine Deiminases (PAD1, -2, and -4) Using Designer Probes.
University Health Network
Profiling Protein Arginine Deiminase 4 (PAD4): a novel screen to identify PAD4 inhibitors.
University of South Carolina
The development of N-a-(2-carboxyl)benzoyl-N(5)-(2-fluoro-1-iminoethyl)-l-ornithine amide (o-F-amidine) and N-a-(2-carboxyl)benzoyl-N(5)-(2-chloro-1-iminoethyl)-l-ornithine amide (o-Cl-amidine) as second generation protein arginine deiminase (PAD) inhibitors.
The Scripps Research Institute
Screening Ultra-Large Encoded Compound Libraries Leads to Novel Protein-Ligand Interactions and High Selectivity.
Astrazeneca
Privileged heterocycles for DNA-encoded library design and hit-to-lead optimization.
Chinese Academy of Sciences
Novel Macrocyclic Peptidylarginine Deiminase Type 4 (PAD4) Inhibitors.
Smith, Gambrell & Russell
Peptidylarginine deiminases 4 as a promising target in drug discovery.
Zhejiang Ocean University
DNA-Encoded Library Screening as Core Platform Technology in Drug Discovery: Its Synthetic Method Development and Applications in DEL Synthesis.
Daegu-Gyeongbuk Medical Innovation Foundation (Dgmif)
Cellular Activity of New Small Molecule Protein Arginine Deiminase 3 (PAD3) Inhibitors.
Yale University
Synthesis and Biological Evaluation of an Indazole-Based Selective Protein Arginine Deiminase 4 (PAD4) Inhibitor.
Yale University
Inhibitors of protein arginine deiminases and their efficacy in animal models of multiple sclerosis.
University Health Network
Noncovalent Protein Arginine Deiminase (PAD) Inhibitors Are Efficacious in Animal Models of Multiple Sclerosis.
University of Toronto
N-(BENZOYL)-PHENYLALANINE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF
Hangzhou Apeloa Medicine Research Institute Co.
FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28
Dana-Farber Cancer Institute
Anilinopyrimidines as haematopoietic progenitor kinase 1 (HPK1) inhibitors
Ariad Pharmaceuticals
SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse model
Sichuan University